Preliminary Data to be Presented Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

London, UK, 19th January 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the preliminary data from the first cohort of patients in the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

Share this article with a friend

Create an account to access this functionality.
Discover the advantages